Research programme: glycogen synthase kinase 3 beta inhibitors

Drug Profile

Research programme: glycogen synthase kinase 3 beta inhibitors

Alternative Names: 9 ING 41

Latest Information Update: 11 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Northwestern University; University of Illinois at Chicago
  • Developer Actuate Therapeutics; Northwestern University; University of Illinois at Chicago
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Preclinical Glioblastoma; Inflammation; Neuroblastoma

Most Recent Events

  • 07 Mar 2017 Research programme: glycogen synthase kinase 3 beta inhibitors is available for licensing as of 07 Mar 2017. https://actuatetherapeutics.com/partnering/
  • 07 Mar 2017 Preclinical trials in Inflammation in USA (unspecified route) before March 2017
  • 07 Mar 2017 Actuate Therapeutics plans the first-in-man phase I trial of 9 ING 41, presumably in Glioblastoma, in early 2017 (Actuate Therapeutics website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top